Skip to main content
67 search results for:

Ixekizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-09-2022 | Axial spondyloarthritis | News | Article

    Successful retreatment of axSpA flare feasible following ixekizumab withdrawal

    Most patients with axial spondyloarthritis who stop taking ixekizumab respond to the treatment when it is reintroduced following disease flare, analysis of COAST-Y data suggests.

  2. 13-05-2021 | Axial spondyloarthritis | News | Article

    COAST-Y supports continued ixekizumab treatment for patients with axSpA

    Patients with axial spondyloarthritis who continue treatment with ixekizumab are less likely to experience flares than those who discontinue the IL-17A inhibitor, trial results suggest.

  3. 14-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article
    News in brief

    Sustained benefits of ixekizumab over adalimumab in PsA

    Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis.

  4. 12-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

    Continuing ixekizumab superior to withdrawal for stable psoriatic arthritis patients

    Patients with psoriatic arthritis who have achieved minimal disease activity on ixekizumab do better if they continue on the drug rather than stopping treatment, show findings from the SPIRIT-P3 study.

  5. 04-05-2020 | Axial spondyloarthritis | News | Article
    approvalsWatch

    Ixekizumab set for EU approval for radiographic, nonradiographic axSpA

    medwireNews : The EMA has adopted a positive opinion recommending approval of the interleukin (IL)-17A inhibitor ixekizumab for axial spondyloarthritis (axSpA).

  6. 07-11-2019 | Ankylosing spondylitis | News | Article
    News in brief

    Sustained benefits of ixekizumab in ankylosing spondylitis

    The benefits of treatment with ixekizumab are maintained for up to 1 year in patients with ankylosing spondylitis, suggest follow-up results from the phase III COAST-V and COAST-W trials.

  7. 26-02-2020 | Psoriatic arthritis | News | Article
    News in brief

    Support for ixekizumab as a long-term treatment option for PsA

    The interleukin-17A inhibitor ixekizumab has consistent efficacy and safety profiles for up to 3 years among patients with psoriatic arthritis and no prior biologic exposure, suggest follow-up results from the SPIRIT-P1 trial.

  8. 10-09-2019 | Ankylosing spondylitis | News | Article
    approvalsWatch

    FDA gives nod to ixekizumab for ankylosing spondylitis

    medwireNews : The indication for ixekizumab has been expanded to include ankylosing spondylitis (AS) in the USA.

  9. 15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

    Ixekizumab tops adalimumab in head-to-head PsA trial

    Findings from the SPIRIT-H2H trial, presented at the EULAR 2019 congress in Madrid, Spain, have demonstrated superior efficacy of ixekizumab versus adalimumab among patients with psoriatic arthritis.

  10. 25-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

    Ixekizumab efficacious in PsA following one or two inadequate anti-TNF responses

    Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

  11. 07-02-2019 | Psoriatic arthritis | News | Article

    Ixekizumab treatment linked to enthesitis, dactylitis improvements in PsA

    A post-hoc analysis of the SPIRIT-P1 and SPIRIT-P2 trials suggests that treatment with ixekizumab is associated with improvements in enthesitis and dactylitis among patients with psoriatic arthritis.

  12. 26-10-2018 | Ankylosing spondylitis | News | Article

    Further evidence for the benefits of ixekizumab in ankylosing spondylitis

    Findings from the COAST-W trial provide support for the IL-17A inhibitor ixekizumab as a treatment option for patients with ankylosing spondylitis and a previous inadequate response or intolerance to TNF inhibitor treatment.

  13. 24-08-2018 | Psoriatic arthritis | News | Article
    Regulatory update

    UK guidance recommends ixekizumab for the treatment of PsA

    Ixekizumab has been recommended by the UK National Institute For Health and Care Excellence as a treatment option for patients with psoriatic arthritis.

  14. 20-08-2018 | Psoriatic arthritis | Highlight | Teaser
    medwireNews feature

    Into the clinic: Ixekizumab for the treatment of PsA

    medwireNews  summarizes the key data supporting the approval of ixekizumab for the treatment of psoriatic arthritis, and discusses its place in the treatment landscape with Philip Mease and Laura Coates.

  15. 20-08-2018 | Psoriatic arthritis | Feature | Article

    Into the clinic: Ixekizumab for the treatment of PsA

    medwireNews  summarizes the key data supporting the approval of ixekizumab for the treatment of psoriatic arthritis, and discusses its place in the treatment landscape with Philip Mease and Laura Coates.

  16. 24-10-2018 | Ankylosing spondylitis | Highlight | Teaser
    medwireNews@ACR/ARHP 2018

    COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

    Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

  17. 23-10-2018 | Ankylosing spondylitis | News | Article

    COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

    Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

  18. 20-08-2018 | Psoriatic arthritis | Feature | Article

    At a glance: Data supporting the approval of ixekizumab for PsA

    A quick-reference guide to the clinical trial data supporting the approval of ixekizumab for the treatment of psoriatic arthritis.

  19. 20-08-2018 | Psoriatic arthritis | Highlight | Teaser
    medwireNews feature

    At a glance: Data supporting the approval of ixekizumab for PsA

    A quick-reference guide to the clinical trial data supporting the approval of ixekizumab for the treatment of psoriatic arthritis.

  20. 02-02-2018 | Psoriatic arthritis | Drug approval | Article
    approvalsWatch

    USA, Europe give nod to ixekizumab for PsA

    The indication for ixekizumab has been expanded to include psoriatic arthritis in the USA and Europe.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.